Justin Schreiber

Chief Executive Officer at LifeMD

Board

Since April 1, 2022

Age

41 years

Education

Holds a BS in International Business from Elizabethtown College and a BA in International Management from the ICN École de Management in Nancy, France.

Tenure

Joined LFMD in 2018 where he initially served as CEO and later took on additional roles including President and Chairman of the Board.

Also at LifeMD

Dennis Wijnker

Chief Technology Officer (CTO)

Jessica Friedeman

Chief Marketing Officer

Marc Benathen

Chief Financial Officer (CFO)

About

Justin Schreiber is a seasoned executive with a diverse background in international business and healthcare consulting, having worked in currency trading and advisory roles before establishing his own ventures.

He joined LFMD in 2018, beginning his tenure as Chief Executive Officer and subsequently taking on further responsibilities as President and Chairman of the Board, demonstrating a steady progression in leadership within the organization.

With a strong educational foundation and extensive experience in both capital markets and investor relations, his contributions to LFMD have been pivotal as he dedicates a significant portion of his time to driving the company’s strategic initiatives.

$LFMD Performance Under Justin Schreiber

Past Roles

Organization	Role	Date Range	Details
LifeMD	CEO and Chairman (Consulting Agreement)	April 2020 - 2022	Held under a consulting agreement before formal CEO appointment
LifeMD	President	2018 - 2021
LifeMD PR, LLC	President	2017 - N/A	Wholly-owned subsidiary in Puerto Rico
LifeMD	Chairman of the Board	2019 - N/A
Private Consulting Business	Investor Relations, Advisory & Capital Raising Consultant	N/A [N/A]	Provided consulting services to small publicly traded companies
Global Healthcare Consulting Firm	Consultant	N/A [N/A]	Worked in a global healthcare consulting firm
Foreign Currency Trading Business	Trader	N/A [N/A]	Worked in the foreign currency trading business

External Roles

Organization	Role	Date Range	Details
JLS Ventures	President and Founder	Present [N/A]	Investment and capital markets advisory firm that invests in emerging growth publicly traded companies

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Salary	$300,000	Annual (2023)	Base salary per employment agreement effective April 1, 2022.
Bonus	$225,000	Annual (2023)	Performance bonus awarded for 2023.
Stock Awards	$355,000	Granted in 2023	Aggregate grant date fair value of restricted stock units; includes 50,000 RSUs granted on November 13, 2023 that vest on January 1, 2024.
Other Compensation	$8,803	2023	Includes company contributions to the 401(k) account.
Long-Term Incentive Awards - Time-Based Vesting	N/A	Vesting per agreed schedule	25,000 shares vested immediately on November 13, 2023; 50,000 shares vesting on January 1, 2024; 75,000 shares vesting on January 1, 2025.

Performance Compensation

Data from FY 2023

Long-Term Incentive Awards - Performance-Based Vesting

75,000 restricted shares are scheduled to vest on March 1, 2024 based on 2023 performance. Specific performance metrics, thresholds, targets, or evaluation conditions are not detailed in the available documents.

Long-Term Incentive Awards - Performance Milestones

Component	Shares	Threshold/Target	Target Date	Grant Date	Additional Details
$100M Performance Milestone Award	100,000	$100 million net revenue with 5% adjusted EBITDA margin	On or before December 31, 2025	November 13, 2023	Restricted shares vest upon achieving the milestone; all shares vest immediately upon a Change in Control; forfeiture conditions apply in cases of misconduct.
$150M Performance Milestone Award	100,000	$150 million net revenue with 10% adjusted EBITDA margin	On or before December 31, 2026	Not explicitly stated	Vesting occurs upon achievement; early vesting may occur upon termination without Cause or for Good Reason, and all shares vest immediately on a Change in Control.
$200M Performance Milestone Award	100,000	$200 million net revenue with 10% adjusted EBITDA margin	On or before December 31, 2027	November 13, 2023	Valuation reference includes a stock price of $8.29 on December 29, 2023 ; standard forfeiture provisions apply; accelerated vesting upon Change in Control.

This table outlines the performance compensation components for 2023, including both performance‐based vesting and milestone awards with their respective targets and conditions.